Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.49 |
| ▸ | HNF4A | P41235 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.45 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3528772 | 0.98 | LDHA (0.53) | LDHAPIK3C3ACMSDHNF4AALDH1A1 | |
| SCHEMBL10203111 | 0.86 | LDHA (0.44) | LDHAPIK3C3ACMSDHNF4ADHFR | |
| SCHEMBL4768064 | 0.86 | AXL (0.46) | LDHAPIK3C3ALDH1A1CAMKK2MAP4K4 | |
| SCHEMBL11064733 | 0.85 | MAP4K4 (0.50) | PIK3C3ALDH1A1MAP4K4AKR1C2AKR1C1 | |
| SCHEMBL27639373 | 0.84 | MCL1 (0.57) | LDHAPIK3C3MCL1MAP4K4AXL | |
| SCHEMBL7093171 | 0.83 | AXL (0.60) | ALDH1A1CAMKK2AXLPRKCISGK1 | |
| Hydrochloric Acid SCHEMBL7093169 | 0.82 | AXL (0.59) | ALDH1A1CAMKK2AXLPRKCISGK1 | |
| SCHEMBL28331820 | 0.82 | AKR1C2 (0.54) | PIK3C3MCL1DHODHMAP4K4AKR1C2 | |
| SCHEMBL4768072 | 0.82 | PSMB5 (0.42) | LDHAPIK3C3ALDH1A1CAMKK2PARP1 | |
| SCHEMBL27603195 | 0.81 | MCL1 (0.61) | LDHAPIK3C3ALDH1A1MCL1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1896421-B1 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1896422-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7790739-B2 | receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one | Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790739-B2 | receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one | Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1896422-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896421-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007050380-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007002254-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002258-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293358-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2003084931-A1 | 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | LDHA 3142/4885PIK3C3 478/4885ACMSD 4837/4885 |
| US-20060293358-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, RET | LDHA 4152/4885PIK3C3 416/4885ACMSD 4824/4885 |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | LDHA 3517/4885PIK3C3 134/4885ACMSD 4872/4885 |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MET, RET, ERBB2 | LDHA 3768/4885PIK3C3 1215/4885ACMSD 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.